The MicroCap Conference on October 5 and the 3rd Annual Dawson James Securities Small Cap Growth Conference on October 19

ANN ARBOR, MI / ACCESSWIRE / September 27, 2017 / ENDRA Life Sciences Inc. ("ENDRA") (NASDAQ: NDRA), a developer of enhanced ultrasound technologies, has been invited to participate at two upcoming conferences in October 2017.

The MicroCap Conference is being held on October 5, 2017 at the Essex House in New York City. ENDRA CEO Francois Michelon and CFO David Wells are scheduled to present on Thursday, October 5 at 1:00 p.m. Eastern time with one-on-one meetings held throughout the conference. The presentation will be webcast live and available for replay at http://wsw.com/webcast/microcapconf5/ndra/ and via the investor relations section of the Company's website at www.endrainc.com. To schedule a meeting, please click here to register for the conference or you may email your meeting request to NDRA@mzgroup.us or call Chris Tyson at (949) 491-8235.

The 3rd Annual Dawson James Securities Small Cap Growth Conference is being held on October 18-19, 2017 at the Wyndham Grand Hotel in Jupiter, Florida. ENDRA CEO Francois Michelon and CFO David Wells are scheduled to present on Thursday, October 19 at 2:00 p.m. Eastern time with one-on-one meetings held throughout the conference. For additional information or to schedule a one-on-one meeting with ENDRA management, please contact your Dawson James representative. You may also email your request to NDRA@mzgroup.us or call Chris Tyson at (949) 491-8235.

About the MicroCap Conference

The MicroCap Conference is an exclusive event dedicated to connecting high-performing small and microcap companies with committed investors. It is an opportunity to be introduced to and speak with management at some of the most attractive companies, learn from various expert panels, and network with other small and microcap investors. For more information, please click here.

About the 3rd Annual Dawson James Securities Small Cap Growth Conference

Dawson James Securities is a full service investment banking firm with research, institutional and retail sales, as well as execution trading and corporate services. Dawson James is hosting its 3rd Annual Small Cap Growth Conference on October 18-19, 2017 at the Wyndham Grand Jupiter at Harbourside Place in Jupiter, Florida. More than 30 public companies are expected to present. The event will feature tracks focused on healthcare, technology & consumer sectors. The conference will include corporate presentations, Q&A sessions, investor one-on-one meetings and networking opportunities. Dawson James welcomes institutional investors, private investors and industry executives to attend this conference. For more information, please click here.

About ENDRA Life Sciences Inc.

ENDRA Life Sciences Inc. ("ENDRA") (NASDAQ: NDRA) is a developer of enhanced ultrasound technologies. ENDRA's Photo-Acoustic Nexus-128 system is currently used by leading global medical researchers to screen and modify disease models with high image quality and volume scanning speed. ENDRA's next generation Thermo-Acoustic Enhanced UltraSound ("TAEUS") is expected to enable clinicians to visualize human tissue composition, function and temperature in ways previously possible only on CT & MRI -- at a fraction of the cost, and at the point-of-care. ENDRA's first TAEUS application will focus on the quantification of fat in the liver, for early detection and monitoring of Non-Alcoholic Fatty Liver Disease, which affects over 1 billion people globally. ENDRA's goal is to bring new capabilities to ultrasound -- thereby broadening access to better healthcare. For more information, please visit www.endrainc.com.

Forward-Looking Statements

This release contains “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, that are intended to be covered by the "safe harbor" created by those sections. Forward-looking statements, which are based on certain assumptions and describe our future plans, strategies, and expectations, can generally be identified by the use of forward-looking terms such as "believe," "expect," "may," "will," "should," "could," "seek," "intend," "plan," "goal," "estimate," "anticipate" or other comparable terms. All statements in this release that are not based on historical fact are forward-looking statements. Forward-looking statements involve inherent risks and uncertainties which could cause actual results to differ materially from those in the forward-looking statements, as a result of various factors including those risks and uncertainties described in the Risk Factors and in Management's Discussion and Analysis of Financial Condition and Results of Operations sections of ENDRA's recently filed Quarterly Report on Form 10-Q, which can be found on the SEC's website at www.sec.gov. ENDRA urges you to consider those risks and uncertainties in evaluating our forward-looking statements. ENDRA caution readers not to place undue reliance upon any such forward-looking statements, which speak only as of the date made. Except as otherwise required by the federal securities laws, ENDRA disclaims any obligation or undertaking to publicly release any updates or revisions to any forward-looking statement contained herein (or elsewhere) to reflect any change in its expectations with regard thereto or any change in events, conditions or circumstances on which any such statement is based.

Company Contact:

David Wells
Chief Financial Officer
(734) 997-0464
investors@endrainc.com
www.endrainc.com

Media & Investor Relations Contact:

MZ North America
Chris Tyson
Managing Director
(949) 491-8235
NDRA@mzgroup.us
www.mzgroup.us

SOURCE: ENDRA Life Sciences Inc.